

Santhera Board Proposes the Election of  
Klaus Schollmeier to the Company's Board

Published: 18:00 01.03.2007 GMT+1 /HUGIN /Source: Santhera  
Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649

Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today that its Board of Directors has decided to propose the appointment of Dr Klaus Schollmeier, the Company's Chief Executive Officer (CEO), to the Board. This appointment would be for a term of three years. Dr Schollmeier's appointment to the Board is subject to the approval at the upcoming Shareholder's Meeting, scheduled for April 23, 2007, in Basel, Switzerland.

Michael Lytton, Chairman of the Board of Directors, commented: "Klaus Schollmeier has been CEO of Santhera since its inception in 2004 and, previously, one of its predecessor companies, Graffinity, since 2003. Klaus Schollmeier has been a main driving force behind the Company's considerable success. Over this period, Santhera has developed an exciting portfolio of neuromuscular drug candidates and has raised close to CHF 190 million in new funds from both private and public investors. The Board believes that, with the addition of Klaus Schollmeier to the Company's Board, Santhera's decision making processes can become even more effective and efficient ensuring high quality and direct information flow between the Board and the Executive Management."

Klaus Schollmeier, CEO, added: "I feel extremely honored by my proposed appointment to the Company's Board. Over the last three years, Santhera has made considerable progress and has created significant value for all of its stakeholders. I consider today's decision as clear sign of the Board's confidence in me, in my executive team, and in the Company's ability to deliver on its goal of becoming one of the leading specialty companies focused on neuromuscular diseases."

\* \* \*

Additional biographical information is available at the Company's website [www.santhera.com](http://www.santhera.com) <<http://www.santhera.com/>> under About us/Executive Management.

For Further Information, Contact

Santhera Pharmaceuticals  
Hans Peter Hasler, Vice-Chairman  
phone: +41 (0)61 906 89 27

Thomas Staffelbach, VP Public & Investor Relations  
phone: +41 (0)61 906 89 47  
[thomas.staffelbach@santhera.com](mailto:thomas.staffelbach@santhera.com) <<mailto:.staffelbach@santhera.com>>

Media Contacts: Citigate Dewe Rogerson  
David Dible  
phone: +44 207 638 95 71

david.dible@citigatedr.co.uk

[https://connector.huginonline.com/staffelbach\\$/News%20releases%20Drafts%20only/david.dible@citigatedr.co.uk](https://connector.huginonline.com/staffelbach$/News%20releases%20Drafts%20only/david.dible@citigatedr.co.uk)